Ravulizumab IV q8w for IgA Nephropathy (ICAN Trial)

"The current information on clinicaltrials.gov shows that this particular trial is not actively seeking participants. Initial posting of the study was on April 30th, 2024, with the most recent update occurring on February 26th, 2024. It's worth noting that while this specific trial is closed for recruitment, there are a total of 508 other trials currently accepting volunteers."

"The primary objective of this investigation, to be assessed from a Baseline through Week 34 timeframe, is the assessment of Glomerular Filtration Rate (eGFR) over a span of 106 weeks. Secondary endpoints encompass achieving a Reduction in 24-hour UPCR ≥ 50% compared to baseline at both Weeks 34 and 106 - evaluated solely during final analysis; tracking the Number of Participants with Composite Kidney Failure Endpoint characterized by various criteria including significant eGFR decline or initiation of dialysis - also evaluated only during final analysis; and observing Change From Baseline in eGFR at Weeks 34, "

"Presently, there are 134 active sites conducting this research. These sites can be found in various locations such as Sr Priest En Jarez, Araucania, Southport, and an additional 131 cities. Opting for the nearest site could reduce the need for extensive travel during your participation."

"Individuals diagnosed with Iga nephropathy and aged between 18 and 130 are eligible to enroll in the study. A total of 450 participants will be recruited for this trial."

"Participants aged 18 years or older but under the age of 130 are eligible for recruitment into this study."

"Our team at Power has assigned a safety rating of 3 to Ravulizumab IV q8w based on the available data. This score reflects the advanced Phase 3 trial, indicating a foundation of efficacy support and extensive safety information."